Congress:
ECR24
Poster Number:
C-16702
Type:
EPOS Radiologist (scientific)
Authorblock:
S. Gruendemann, F. Kreis, P. Severin, G. Jost, J. Lohrke, H. Pietsch; Berlin/DE
Disclosures:
Stephan Gruendemann:
Employee: Bayer AG
Felix Kreis:
Employee: Bayer AG
Philipp Severin:
Employee: Bayer AG
Gregor Jost:
Employee: Bayer AG
Jessica Lohrke:
Employee: Bayer AG
Hubertus Pietsch:
Employee: Bayer AG
Keywords:
Contrast agents, MR, Contrast agent-intravenous, Physics, Safety, Toxicity
In this study some physico-chemical properties of the next generation, high relaxivity MRI contrast agents gadopiclenol (commercially available in US, approved in EU) and gadoquatrane (currently in clinical phase 3) were compared. Both exhibit r1 relaxivities which are >2 fold higher compared to gadobutrol with a notable distribution due to human plasma variability. While there was no detectable release of gadolinium in blood plasma for gadoquatrane, gadopiclenol showed an observable gadolinium release over a period of 15 days. This high stability of gadoquatrane is also reflected by a slower release of Gd3+ at low pH compared to gadopiclenol.